Bio­gen makes cau­tious bet on dry AMD as part­ner Cat­a­lyst Bio moves an­ti-C3 drug to­ward the clin­ic

Mov­ing deep­er in­to oph­thal­mol­o­gy, Bio­gen has picked up a pre­clin­i­cal can­di­date for dry age-re­lat­ed mac­u­lar de­gen­er­a­tion.

Their part­ner of choice is Cat­a­lyst Bio, a biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER